Texas Round-Up: Lone Star State Ropes in More than $4 Billion in Active Capital Project Investment from Pharmaceutical-Biotech Sector
Attachment: Texas Pharma-Biotech Spending, Nov. 2015
SUGAR LAND--November 5, 2015--Reported by Annette Kreuger, Industrial Info Resources, Incorporated (Sugar Land, Texas)--While more commonly known as the land where oil and chemical industry workers roam, Texas is steadily becoming home to a growing number of scientists from the pharmaceutical and biotech fields. A recent survey of all active capital projects within the state, and sourced from the sector, revealed a healthy mix of 56 public and private projects with a staggering total investment value (TIV) of $4.15 billion.
Within this article: Details on pharmaceutical and biotech projects in Texas, including those from companies such as GlaxoSmithKline (NYSE:GSK) and Lonza Group.
